<DOC>
	<DOCNO>NCT03031418</DOCNO>
	<brief_summary>The purpose research study investigate new validate urine test predict likelihood high grade prostate cancer initial prostate biopsy The current protocol two objective ; one ass evaluate performance urine test men already schedule initial prostate needle biopsy ( cohort ( group ) 1 ) two , evaluate result urine test influence decision process determine whether perform prostate biopsy ( cohort ( group ) 2 ) .</brief_summary>
	<brief_title>Clinical Evaluation 'ExoDx Prostate IntelliScore ' ( EPI )</brief_title>
	<detailed_description>Primary Objective ( ) - Confirm performance ExoDx Prostate ( IntelliScore ) ( EPI ) utilize designate collection vessel men present initial prostate biopsy elevate Prostate-specific antigen ( 2-10 ng/mL ) . - Evaluate impact confirm ExoDx Prostate ( IntelliScore ) decision perform initial prostate biopsy men present elevate Prostate-specific antigen ( 2-10 ng/mL ) . Secondary Exploratory Objectives - Assess physician satisfaction ExoIntelliScore Prostate report include test result presentation , graphic interpretation . - Assess patient satisfaction ease understand test result role decision process biopsy . - Determine medical economic impact ExoIntelliScore Prostate prostate biopsy decision process . - Correlation ExoIntelliScore Prostate score actual biopsy result .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>50 year age Clinical suspicion prostate cancer Elevated Prostatespecific antigen : 2.0 10 ng/ mL No clinical history prior negative biopsy History prior prostate biopsy . Use medication hormone know affect serum Prostatespecific antigen level within 36 month study enrollment . Clinical symptom urinary tract infection ( include prostatitis ) time enrollment . History prostate cancer . History invasive treatment benign prostatic hypertrophy ( Benign Prostatic Hyperplasia ) low urinary track symptom within 6 month study enrollment . No known hepatitis ( type ) and/or HIV document patient 's medical record . Patients history concurrent renal/bladder tumor .</criteria>
	<gender>Male</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>